{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T15:56:29Z","timestamp":1774108589778,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intravenous immunoglobulin (IVIG) has been widely used to treat immune-mediated neuromuscular disorders. The relationship between IVIG and cancer is unclear. Preclinical studies have suggested that IVIG may influence cellular mechanisms pertinent to cancer development. This hypothesis is supported by clinical evidence, predominantly through case reports, although these findings are limited in scope and methodological rigor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was conducted on patients receiving chronic IVIG treatment for Myasthenia Gravis (MG) and chronic immune demyelinating polyradiculoneuropathy (CIDP), at our tertiary medical center between 2000 and 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 436 patients with MG and 102 patients with CIDP. Patients were divided into IVIG and non-IVIG treated in each of the disease groups. Seventy-five and 64 patients received IVIG in MG and CIDP groups, respectively. Cancer incidence was counted if it appeared at least 1 year after the diagnosis of MG or CIDP. In the MG group, cancer incidence was 12 \/ 75 (16%) among IVIG-treated patients compared to 87\/350 (25%) in the MG-non-IVIG group (<jats:italic>p<\/jats:italic> =\u202f0.09). Excluding mild MG cases, who were treated only by pyridostigmine, cancer incidence in the MG-non-IVIG group increased to 72\/250 (28.8%), significantly higher than in the IVIG-MG group, <jats:italic>p<\/jats:italic> =\u202f0.01. For CIDP patients receiving IVIG, incidence of cancer was 6\/59 (10%), while in the non-IVIG-treated CIDP group, it was 9\/34 (26%) (<jats:italic>p<\/jats:italic> =\u202f0.03). Analyzing all IVIG-treated patients together (of both disease groups) showed a negative correlation between \u201ctime on IVIG treatment\u201d and cancer (<jats:italic>p<\/jats:italic> =\u202f0.001). Using logistic regression, we observed a negative coefficient for IVIG exposure (\u22120.03, <jats:italic>p<\/jats:italic> =\u202f0.004), indicating that an increase in time from diagnosis is associated with a decreased likelihood of developing cancer in the IVIG-treated group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chronic IVIG therapy may be associated with a reduced incidence of cancer, particularly among patients with CIDP. Additionally, we found a negative correlation between duration of IVIG treatment and cancer incidence, suggesting a potential protective effect of long-term IVIG exposure. To our knowledge, this is the first study to explore the relationship between sustained IVIG therapy and long-term cancer risk in neuromuscular autoimmune diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1571160","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:10:19Z","timestamp":1750738219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Malignancy in neuromuscular patients on chronic IVIG"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohamed","family":"Khateb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elian","family":"Bahous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Abu Zant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahar","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1212\/wnl.59.12_suppl_6.s28","article-title":"Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy","volume":"59","author":"Lemm","year":"2002","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of intravenous immune globulin in immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/wnl.51.6_suppl_5.s2","article-title":"Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2018","journal-title":"Blood Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.12.034","article-title":"IVIg in the chronic management of myasthenia gravis: is it enough for your money?","volume":"338","author":"Dalakas","year":"2014","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11940-010-0065-x","article-title":"Pathogenesis and treatment of anti-MAG neuropathy","volume":"12","author":"Dalakas","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1212\/WNL.0000000000012932","article-title":"Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes","volume":"97","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2078","DOI":"10.1212\/WNL.0000000000011792","article-title":"Expanding the spectrum of chronic immune sensory polyradiculopathy: CISP-plus","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/intimm\/11.8.1247","article-title":"Gamma-globulin inhibits tumor spread in mice","volume":"11","author":"Shoenfeld","year":"1999","journal-title":"Int Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3892\/ijo.21.4.875","article-title":"IVIg to prevent tumor metastases (review)","volume":"21","author":"Fishman","year":"2002","journal-title":"Int J Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/imt.16.9","article-title":"The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?","volume":"8","author":"Corbi","year":"2016","journal-title":"Immunotherapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/cells10020355","article-title":"NF-\u03baB in Cancer immunity: friend or foe?","volume":"10","author":"Lalle","year":"2021","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-kappaB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1196\/annals.1423.061","article-title":"Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin","volume":"1110","author":"Damianovich","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1423.032","article-title":"Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma","volume":"1110","author":"Schachter","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.v99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2249.2009.04026.x","article-title":"Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation","volume":"158","author":"Schwartz-Albiez","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/intimm\/dxp070","article-title":"Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg)","volume":"21","author":"Damianovich","year":"2009","journal-title":"Int Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1196\/annals.1361.118","article-title":"Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss","volume":"1051","author":"Sapir","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CJI.0000000000000380","article-title":"Role of IVIG in the treatment of autoimmune conditions with concurrent immune checkpoint inhibitors for metastatic Cancer","volume":"44","author":"Punekar","year":"2021","journal-title":"J Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/1097-0142(19940601)73:11<2859::aid-cncr2820731132>3.0.co;2-p","article-title":"Regression of Kaposi\u2019s sarcoma after intravenous immunoglobulin treatment for polymyositis","volume":"73","author":"Carmeli","year":"1994","journal-title":"Cancer"},{"key":"ref24","first-page":"698","article-title":"Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment","volume":"3","author":"Shoenfeld","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3892\/ijo.20.4.839","article-title":"A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model","volume":"20","author":"Merimsky","year":"2002","journal-title":"Int J Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/14740338.1.2.153","article-title":"IVIG in autoimmunity and cancer--efficacy versus safety","volume":"1","author":"Sherer","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0002-9343(84)90344-9","article-title":"Use of intravenous immunoglobulin in chronic lymphocytic leukemia","volume":"76","author":"Besa","year":"1984","journal-title":"Am J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0118989","DOI":"10.1371\/journal.pone.0118989","article-title":"Cytomegalovirus and Epstein-Barr virus in breast cancer","volume":"10","author":"Richardson","year":"2015","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/cncr.10905","article-title":"Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages","volume":"95","author":"Shapiro","year":"2002","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s1388-2457(00)00307-2","article-title":"SFEMG in ocular myasthenia gravis diagnosis","volume":"111","author":"Padua","year":"2000","journal-title":"Clin Neurophysiol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mus.24745","article-title":"Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: review of recent literature","volume":"52","author":"Chiou-Tan","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/brb3.70143","article-title":"The association between myasthenia gravis and higher Extrathymic Cancer risk","volume":"15","author":"Khateb","year":"2025","journal-title":"Brain Behav"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1586031","DOI":"10.3389\/fneur.2025.1586031","article-title":"Mortality risk in patients with myasthenia gravis","volume":"16","author":"Khateb","year":"2025","journal-title":"Front Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00415-009-5091-9","article-title":"Risk factors for tumor occurrence in patients with myasthenia gravis","volume":"256","author":"Citterio","year":"2009","journal-title":"J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e2966","DOI":"10.1212\/WNL.0000000000012050","article-title":"Clinical utility of Striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/ard.51.4.437","article-title":"Increased risk of cancer in patients with systemic lupus erythematosus","volume":"51","author":"Pettersson","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0002-9343(85)90240-2","article-title":"Cancer and rheumatoid arthritis: epidemiologic considerations","volume":"78","author":"Prior","year":"1985","journal-title":"Am J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1191\/096120301678646128","article-title":"Systemic lupus erythematosus and the risk of malignancy","volume":"10","author":"Cibere","year":"2001","journal-title":"Lupus"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1504496","DOI":"10.3389\/fimmu.2025.1504496","article-title":"Survival and autoimmune risks post-thymectomy","volume":"16","author":"Tsirkin","year":"2025","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin Cancer in organ transplant recipients: systematic review and Meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transplant"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/wnl.46.6.1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study","volume":"46","author":"Confavreux","year":"1996","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1571160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:10:19Z","timestamp":1750738219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1571160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":44,"alternative-id":["10.3389\/fneur.2025.1571160"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1571160","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1571160"}}